We rely on advice from our scientific advisors who assist us with internal triage of new applications and assessment of completed projects.
Professor Jim Owen is an Emeritus Professor of Molecular Medicine at UCL. His research focused on lipoprotein metabolism, cell signalling and gene-based therapeutics, encompassing liver, cardiovascular and renal diseases, parasitic infections and Alzheimer’s disease.
MD (Lond), FRCP (Lond), FRCP (Edin), FRCPath, FFPM
Past President of the Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians (UK)
Keith is a consultant expert for Rosetrees Trust and the National Institute of Health and Care Excellence (NICE). He is a specialist in pharmaceutical medicine. He was originally a clinical haematologist and haematopathologist in the UK and USA. He is a Past President of the Faculty of Pharmaceutical Medicine (2012-15).
Prior to joining Rosetrees, Dr. Petra Disterer was a senior post-doctoral scientist at UCL working on oligonucleotide therapeutics. In addition to working for Rosetrees, as a scientific advisor and meeting our researchers, Petra works as a science writer for the Oligonucleotide Therapeutics Society.
Pat has over 20 years’ experience of developing and managing Wellcome Trust funding programmes, mainly in the areas of infection and immunity, populations and public health, and molecular genetics. She represented the Wellcome Trust in partnerships with other funders, including the Malaria Genome Project, the Gates Grand Challenges, Human Heredity and Health in Africa (H3Africa), and the Public Health Centres of Excellence Initiative. She was also a Director of UK Biobank and has served on the Councils of the Royal Society of Biology and the Microbiology Society.
Dr Ioannis Papaioannou is a lecturer in the Integrated Medical Sciences programme at UCL. He has experience in both academic and industrial translational research. His primary fields of expertise are molecular/cell biology, drug delivery and transcriptomics.
Dr. Vassileva has extensive experience in research and innovation across the academic, regulatory, industry and publishing sectors. She obtained her HonBSc in Human Biology, MSc in Cancer Genetics and Pathobiology, and PhD in Pharmaceutical Sciences from the University of Toronto.
She has worked at Imperial College London, University College London, Queen Mary University London, and University of Toronto. She has also worked at the European Medicines Agency and at Nature Reviews Clinical Oncology. Recently, she joined Blue Earth Diagnostics, where she leads the Translational Science Programme.
Dr. Vassileva is on the Editorial Board of the European Journal of Nuclear Medicine and Molecular Imaging Research, and peer-reviewers for numerous scientific journals and research funding agencies, providing scientific advice to scientists and clinicians worldwide.